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Introduction: Most patients diagnosed with non-small cell lung
cancer (NSCLC) die within the first few years after diagnosis.
However, only little is known about those who have survived these
first years. We aimed to study conditional 5-year relative survival
rates for NSCLC patients during long-term follow-up.
Methods: All 12,148 patients aged 45 to 74 years diagnosed with
stage I–III NSCLC between 1989 and 2008 in the Netherlands were
derived from the Netherlands Cancer Registry. Conditional 5-year
relative survival was calculated for every additional year survived
up to 15 years.
Results: Conditional 5-year relative survival rapidly improved with
every year survived up to 4 to 5 years after diagnosis. However, a
significant excess mortality of 20 to 40% remained. Conditional
5-year relative survival for those aged 45 to 59 years did not exceed
80% for survivors with stage I or II disease and remained just more
than 70% for those with stage III disease. For those aged 60 to 74
years, these proportions were 70%, 65%, and 60%, respectively.
Conclusions: A significant excess mortality remains in lung cancer
after years which may be explained by excess risk of death due to
smoking-related comorbidity in these patients. Caregivers should
use this information for planning optimal cancer surveillance and
informing cancer survivors about their actual prognosis.
Key Words: Conditional survival, Non-small cell lung cancer,
Long-term survivors, Excess mortality.
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Lung cancer is one of the most frequent cancers in theNetherlands with more than 10,000 new cases annually
(www.ikcnet.nl). It is the most frequent cause of cancer death
in the Netherlands with almost 10,000 deaths in 2008 (www.
cbs.nl). Prognosis for lung cancer has remained poor.1 More
than 50% of all patients diagnosed with lung cancer die
within 1 year.1 As lung cancer is very lethal, most studies
only focus on the first 5 years after diagnosis, whereas little
attention is given to the relatively few (but absolutely many)
patients who survive the first 5 years.
Survival estimates for cancer patients are traditionally
reported from the time of diagnosis. As many patients with
lung cancer die within the first year after diagnosis, these
survival projections are not valid for patients who have
already survived a period of time after initial diagnosis and
treatment. Conditional survival analysis is a method for
estimating the survival rate, given the precondition of having
already survived a certain length of time.2 Conditional sur-
vival can be used by caregivers for planning optimal cancer
surveillance and informing cancer survivors about their actual
prognosis.3,4
In this study, we estimated conditional 5-year relative
survival rates for non-small cell lung cancer (NSCLC) pa-
tients, according to age and tumor stage for each additional
year survived up to 15 years after diagnosis.
METHODS
Data Collection
Population-based data from the nationwide Netherlands
Cancer Registry, which was started in 1989 and maintained
and hosted by the Comprehensive Cancer Centers, were used.
The Netherlands Cancer Registry is based on notification of
all newly diagnosed malignancies in the Netherlands by the
automated pathological archive (Pathological Anatomical
National Automated Archives). Additional sources are the
national registry of hospital discharge diagnoses, which ac-
count for up to an extra 8% of new cases. Information on
patient characteristics such as gender and date of birth, as
well as tumor characteristics such as date of diagnosis,
subsite (International Classification of Diseases for Oncology
[ICD-O-3]), histology, stage (Tumor Lymph Node Metastasis
[TNM] classification), and grade, are obtained routinely from
the medical records about 9 months after diagnosis. The
quality of the data is high, due to thorough training of the
registrars and computerized consistency checks at regional
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and national levels. Completeness is estimated to be at least
95%.5 In addition to passive follow-up through the hospitals,
date of death is also retrieved from the municipal personal
records database (Gemeentelijke Basis Administratie). This
database contains all deaths or emigrated persons in the
Netherlands since October 1994. For patients diagnosed be-
fore October 1994, follow-up was completed by merging
with municipality death records or with the Central Bureau
for Genealogy, which registers all deaths in the Netherlands.
For this study, all cases diagnosed with invasive pri-
mary NSCLC stage I–III in the period 1989–2008 in the
Netherlands were included (N  12,148). Follow-up period
1989–2009 was used. Patients younger than 45 years and
older than 74 years were excluded from the analysis, as well
as cases diagnosed at autopsy. Only 4% of all patients were
diagnosed below age 45. Patients aged 75 years or older were
excluded, because conditional survival estimates are unreli-
able as a very long follow-up is needed. Age was divided in
two groups (45–59 and 60–74 years). Stage was based on the
pathological TNM classification in case patients underwent
surgery. Otherwise, clinical stage was used.
Statistical Analyses
Relative survival is an approximation for disease-spe-
cific survival. It is calculated as the absolute survival among
cancer patients divided by the expected survival of a compa-
rable group from the Dutch general population (same period,
age, and gender). Expected survival was calculated from
population life tables, according to the Ederer II method.6
Period analysis7–9 was used to provide up-to-date survival
estimates; all observations included in the analysis are left-
truncated at the beginning of the period of interest, in addition
to being right-censored at its end. Furthermore, hybrid anal-
ysis was used10 to enable the estimation of even more up-to-
date survival for situations in which mortality data (follow-up
of the study population) are more up-to-date than incidence
data. Five-year relative survival rates were calculated for
every additional year survived up to 15 years after diagnosis,
conditional on being alive at the beginning of that year
(conditional 5-year relative survival). Conditional survival
was calculated for 15 years age groups according to stage of
disease. Results for males and females were not significantly
different; therefore the results for males and females were
combined. We presented only conditional relative survival
estimates with a SE 5% of the survival rate.
When conditional 5-year relative survival has reached
95%, there is hardly any excess mortality for a group of
patients. For the calculation of conditional 5-year relative
survival estimates, a saturated Poisson regression model for
period analysis was used.11 SEs of the survival estimates were
calculated using the delta method. Calculations were per-
formed with SAS software (SAS system 9.2; SAS Institute,
Cary, NC). More detailed data are available in a web-based
tool (www.dutchcancersurvival.com).
RESULTS
The conditional 5-year relative survival rate for
NSCLC patients did not exceed 95%, meaning that a signif-
icant long-term excess in mortality remained (Table 1). In
addition, within each stage group, conditional 5-year relative
survival remained lower for elderly as compared with
younger patients. The numbers of patients available for the
analysis and the last year for which a reliable estimate for the
conditional 5-year relative survival could be estimated is
given in Table 1. Details for each subgroup are described
later.
Relative Survival and Conditional Relative
Survival by Age
Five-year relative survival at diagnosis was signifi-
cantly higher for patients aged 45 to 59 years (31%) com-
pared with those aged 60 to 74 years (25%) (Figure 1). For
those aged 45 to 59 years, conditional 5-year relative survival
improved steeply with every additional year survived up to 4
years after diagnosis (75%). Thereafter, it slightly increased
to 80% (Figure 1). For those aged 60 to 74 years, conditional
5-year relative survival also steeply improved up to 5 years
after diagnosis to 66% but remained stable thereafter. This
has resulted in an increased difference in conditional 5-year
relative survival between the age groups with every addi-
tional year survived.
TABLE 1. Conditional Survival of Non-small Cell Lung Cancer Patients Aged 45–74 yr Diagnosed between 1989 and 2008 in
the Netherlands (N  12,148)
Stage Age (yr)
No. of Patients Available
for (Conditional) Relative
Survival After Year
Reliable Estimate
5-yr Conditional
Survival up to Yeara
5-yr Relative Survival
at Diagnosis (95% CI)
Conditional 5-yr
Relative Survival (%)
0 5 10
At 5 yr
(95% CI)
At 10 yr
(95% CI)
I 45–59 2496 1346 554 15 64 (62–65) 79 (77–81) 82 (79–85)
60–74 5619 2365 642 13 49 (48–50) 68 (67–70) 69 (65–72)
II 45–59 650 336 142 11 43 (40–46) 78 (74–82) 77 (71–84)
60–74 1131 421 112 8 31 (29–33) 64 (60–69) —
III 45–59 860 361 118 10 12 (11–12) 68 (64–72) 73 (66–80)
60–74 1392 418 89 7 8 (8–8) 58 (54–62) —
a SE 5% of survival rate.
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Relative Survival and Conditional Relative
Survival by Stage
Although relative survival at diagnosis for all age
groups combined was clearly different between stage groups
(Figure 2), the differences became smaller with time after
diagnosis. For those alive 4 years after diagnosis, conditional
5-year relative survival was similar for patients with stage I or
II disease (about 75%). However, conditional 5-year relative
survival rates for patients with stage III disease remained
significantly lower (about 65%) than those for patients with
stage I or II disease (Figure 2).
Relative Survival and Conditional Relative
Survival by Age within Each Stage Group
Five-year relative survival at diagnosis for patients with
NSCLC stage I was significantly lower for those aged 60 to 74
years (49%) compared with those aged 45 to 59 years (64%).
For both age groups, conditional 5-year relative survival
strongly increased up to 5 years after diagnosis but flattened
thereafter. Conditional 5-year relative survival rates for those
aged 45 to 59 years remained about 80%, whereas those for
patients aged 60 to 74 years did not exceed 70%, even for those
alive more than 10 years after diagnosis (Figure 3A).
FIGURE 1. Conditional 5-year relative sur-
vival for every additional year survived after
initial diagnosis of non-small cell lung can-
cer (NSCLC) according to age.
FIGURE 2. Conditional 5-year relative sur-
vival for every additional year survived after
initial diagnosis of non-small cell lung can-
cer (NSCLC) according to stage.
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For stage II NSCLC patients, 5-year relative survival
at diagnosis was also significantly lower for patients aged
60 to 74 years (31%) compared with those aged 45 to 59
years (43%). Conditional 5-year relative survival rates
strongly increased for patients having survived up to 4
years after diagnosis, whereafter conditional 5-year rela-
tive survival remained stable at almost 80% and about
65%, respectively (Figure 3B) (almost similar to survivors
with stage I NSCLC).
Five-year relative survival at diagnosis for patients
with stage III NSCLC was significantly lower for those
aged 60 to 74 years (only 8%) than for patients aged 45 to
59 years (12%). For both age groups, conditional 5-year
relative survival strongly increased up to 5 years after
diagnosis but flattened thereafter. Conditional 5-year rel-
ative survival rates for those aged 45 to 59 years remained
just more than 70%, whereas those for patients aged 60 to
74 years did not exceed 60%, even for those still alive 7
years after diagnosis (Figure 3C).
DISCUSSION
Lung cancer is a very lethal disease. More than 50% of
all patients die within 1 year after diagnosis. As many
patients with lung cancer die within the first year after
diagnosis, standard survival estimates that are provided at
diagnosis are not valid for patients who have already survived
a period of time after initial diagnosis and treatment. We have
estimated prognosis for those who have survived the first
years after diagnosis with conditional survival analysis. Al-
though prognosis improved with every additional year sur-
vived up to 4 to 5 years after diagnosis, a considerable excess
mortality compared with the general population remained.
It is reasonable to assume that patients have hardly any
excess mortality when conditional 5-year relative survival
exceeds 95% (survival is then almost similar to the general
population with the same age structure). Although this phe-
nomenon has been described for other tumors with a more
favorable prognosis than lung cancer,4,12–19 conditional
5-year relative survival for lung cancer patients in our study
FIGURE 3. Conditional 5-year relative survival for every additional year survived after initial diagnosis of non-small cell lung
cancer (NSCLC) according to age and stage. A, stage I; B, stage II; C, stage III.
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remained less than 80%. This means that these patients
remain to have a poorer survival compared with the general
population with the same age structure. Potential explana-
tions include late recurrences, second tumors, late side effects
of treatment, or a higher comorbidity mortality rate associ-
ated with cancer-related risk factors. Especially the excess
mortality due to comorbidity associated with smoking, such
as chronic obstructive pulmonary diseases (COPDs) and
cardiovascular diseases (CVDs), seems to play a role among
patients with lung cancer. The prevalence of COPD and CVD
has been shown to be more than 25% in newly diagnosed
lung cancer patients.20 A previous publication has shown that
smoking may influence survival in cancer patients through
effects on respiratory and vascular diseases.21 Among Amer-
ican patients with stage I NSCLC who underwent lobectomy,
the probability of dying of lung cancer decreased over time,
and the probabilities of dying of lung cancer and dying of
CVDs became equivalent if patients survived to 7 years after
lobectomy.22 This point was reached even earlier at higher
age. As mortality of CVDs has been decreasing in the
Netherlands,23 this point will probably be reached later in
more recently diagnosed patients.
Second tumors occur in up to 10% of lung cancer
survivors.24,25 The majority of second tumors following
NSCLC were diagnosed within 1 year.26
For evaluating the influence of late side effects on
excess mortality, it would be interesting to stratify analyses
according to treatment. Especially evaluating late side effects
of chemotherapy and radiotherapy would be interesting. In
addition, refinements in surgery and perioperative care, ra-
diotherapy, and chemotherapy have been made which have
led to a slight improvement in survival over time.27–29 How-
ever, stratification according to treatment (in addition to stage
and age) would lead to subgroups that are too small to
estimate valid conditional 5-year relative survival rates.
Therefore, treatment was not included in these analyses.
Relative survival at diagnosis has been reported to be
more favorable for younger than for older patients with
NSCLC.20 Although previous studies have shown that the
prognostic influence of age on conditional survival of most
cancers largely disappeared after patients survived for 5 to 10
years,4,12,30 in our study the effect of age on conditional
survival of lung cancer remained and even became stronger
over time since diagnosis. The same was observed in popu-
lation-based French,14 Danish,2 and American studies.31 This
indicates that conditional relative survival remains poorer for
elderly, probably because they have more pack-years of
smoking and are therefore at increased risk of dying from
smoking-related comorbidity, of which the prevalence is
higher at older age.20,22
Relative survival at diagnosis was also clearly different
for the stage groups. We have shown that initial differences in
survival between stage I and II disappeared after 4 years, but
conditional 5-year relative survival remained poorer for pa-
tients who were diagnosed with stage III disease. Previous
studies among patients with colorectal, breast, and lung
cancers and melanoma have shown that initial differences
between stage groups also became smaller over time or even
disappeared.4,12,15,17,19,30,32–34 This reflects the fact that pa-
tients with initially the poorest prognosis had the greatest
improvement in 5-year conditional relative survival. Many of
the patients with a very poor prognosis die within the first
years, leaving the fittest patients and those who responded
well to treatment. The remaining excess mortality for those
with stage III probably indicates that the risk of recurrences
or late side effects of treatment (radiotherapy and/or chemo-
therapy for stage III) remains higher than for those with stage
I or II disease. A revision in TNM classification in the late
1990s (part of previous stage IIIA was classified as stage IIB
after 1999 in the Netherlands) and stage migration due to
better diagnostic techniques could also have played a role, as
estimates for conditional 5-year relative survival for patients
who have already survived for more than 10 years were based
on patients diagnosed before 2000.
For estimating conditional 5-year relative survival esti-
mates up to 15 years after diagnosis, a long-lasting database is
needed. For our study, data of patients diagnosed with NSCLC
in the Netherlands between 1989 and 2009 were used.
We included the most up-to-date information available by per-
forming the so-called “period survival analysis.”35 As 5-year
survival of Dutch patients with NSCLC has slightly improved
from 14.8% in 1989–1993 to 16.1% in 2004–2009,36 condi-
tional survival has probably improved over time. Due to the
relatively small numbers of cancer survivors among patients
with lung cancer, we unfortunately could not provide conditional
survival estimates by period of diagnosis. In addition, stage
migration has probably played a role because of better staging
techniques.36 For the interpretation of results, one should take
stage migration and new treatment modalities into account.
Opposite long-term effects on conditional survival can be ex-
pected from a lower tumor relapse risk and an increased cardio-
vascular risk from adjuvant chemotherapy. The presented results
are also strongly dependent on the context of the population
under study (especially frequency of comorbidity, smoking hab-
its). In the Netherlands, the proportion of male smokers used to
be very high in the 1950s and 1960s (90%) but has decreased
thereafter to 28% in 2010 (www.stivoro.nl).37 Among females,
the proportion of smokers was about 25% in 1960 but increased
to about 40% in the 1970s, whereafter it decreased to 26% in
2010. Among Dutch patients diagnosed with lung cancer, the
prevalence of comorbidity is about 50% among those younger
than 65 years and 60 to 70% among those aged 65 years or older.
The most common comorbid conditions are CVDs (25–30%)
and COPDs (25–30%).38 For Dutch patients included in our
study, 5-year relative survival rates at diagnosis were somewhat
lower as compared with Surveillance, Epidemiology and End
Results (SEER) data for American patients: 47%, 32%, and 8%
for stage I, II, and III, respectively, in our study compared with
52% for American lung cancer patients with localized disease
and 24% for American lung cancer patients with regional dis-
ease (source: SEER website). The SEER database is built on
28% of the US population, whereas our results are based on
nearly all cancer patients. Although the patients included in the
SEER are comparable to the general US population regarding
income, education, and other parameters, it remains uncertain
whether this sample is strictly comparable with the whole
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population like in the Dutch registries. Within Europe, lung
cancer survival rates for Dutch patients were among the high-
est.39 As populations differ between countries, conditional sur-
vival analyses should be conducted on a regular basis in the
existing cancer registries worldwide with a view of predicting
the prognosis in long-term NSCLC survivors in an appropriate
(context-specific) way.
Conditional relative survival up to 15 years after diag-
nosis may serve a meaningful role in cancer surveillance
research. As most recurrences and side effects of treatment
occur within the first 2 years, in the current Dutch guidelines
follow-up every 3 months is advised for the first year, every
6 months for the second year, and once a year for the
following years up to at least 5 years after diagnosis
(www.oncoline.nl). We have shown, however, that excess
mortality remains even after 5 years. This means that a longer
follow-up may be warranted. As there seems to be a shift
from excess mortality due to lung cancer toward excess
mortality due to CVDs, follow-up after 5 years should prob-
ably be performed by a general practitioner or a cardiologist.
We are currently merging our data with causes of death
(provided by Statistics Netherlands) for giving insight into
the distribution of causes of death by year after diagnosis.
The results will be provided at the website www.dutchcan-
cersurvival.com when these data are available.
In conclusion, the prognosis for NSCLC survivors
largely improved with each additional year survived up to 4
to 5 years after diagnosis. As lung cancer is very lethal, most
studies only focus on the first 5 years after diagnosis, whereas
little attention is given to the relatively few (but absolutely
many) patients who survive the first 5 years. We have shown
that a significant excess mortality remains. Caregivers should
use this information for planning optimal cancer surveillance
and informing cancer survivors about their actual prognosis.
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